HOME >> BIOLOGY >> NEWS
ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 11, 2007). ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today the publication of a report in the prestigious Nature publication Leukemia confirming the positive clinical activity of the company's lead compound, Ceflatonin against Gleevec-resistant, chronic myeloid leukemia (CML) associated with the T315I Bcr-Abl mutation.

The T315I mutation is known to confer resistance to both Gleevec (imatinib mesylate) and second-generation tyrosine kinase inhibitors (dasatinib and nilotinib). Recent publications indicate that the incidence of T315I-associated resistance is increasing and confirm that this mutation is likely to become the prevalent mutation in those who fail tyrosine kinase inhibitor therapy.

The publication by Dr. Laurence Legros of the Hpital Archet, Nice, France and colleagues describes the treatment with Ceflatonin (homoharringtonine, HHT) of a Gleevec-resistant, chronic-phase CML patient with the T315I Bcr-Abl mutation. The authors report that the patient experienced a 50 percent reduction of T315I Bcr-Abl levels within 2.5 months of treatment initiation, and the complete disappearance of the mutation within 5.5 months of treatment. Complete hematological response (CHR) was achieved after three cycles of therapy.

Based on the clinical results, the authors believe that the rapid and complete disappearance of the T315I mutation might suggest a particular sensitivity of this mutation to HHT. The authors conclude that HHT "may provide an alternative therapeutic treatment option for CML patients with the T315I mutation, for whom therapies have been previously lacking."

The authors also noted some hematologic toxicities (neutropenia, thrombocytopenia and anemia), but confirmed that the toxicity of HHT was "easy to manage".

"We are delighted with this publication that reinforces our belief in the potential of Ceflatonin to treat patient
'"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
11-Jun-2007


Page: 1 2

Related biology news :

1. ChemGenex reports successful personalized dosing of Quinamed at ASCO
2. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
3. ESA announces 2007 award recipients
4. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
5. Conservation Leadership Program announces 2007 awardees
6. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
7. Revolutionary global environment fund announces $50M expansion
8. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
9. Cell Press announces new partnership with the American Society of Human Genetics
10. Minister Lunn announces $39.6M for next phase of mountain pine beetle response
11. BioMed Central announces new interdisciplinary Biofuels Journal

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio ... findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host disease ... hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, this ...
(Date:7/1/2020)... (PRWEB) , ... July 01, 2020 , ... ... that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, ... company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... biopharmaceutical R&D, today announced that it has entered into a multi-year contract ... (Multiclonics®), to support their translational and clinical research strategy to discover and ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... solutions in complex indoor environments, announced today that Derek Fournier has been appointed ... of Chairman of the Board, effective immediately. , “DeCurtis Corporation has been ...
(Date:6/23/2020)... NEW YORK (PRWEB) , ... June 22, 2020 ... ... profiling its lead glutamine antagonist, DRP-104, will be presented June 22-24 during the ... anti-cancer effects of DRP-104; and, the other profiles the potent, consistent single agent ...
(Date:6/19/2020)... ... , ... The Vitaspace project was founded by the famous Russian ... life and find a way (medicine or technology) that will help to preserve youth, ... scientists from all over the world, doctors, and all people who care. , The ...
(Date:6/11/2020)... , ... June 09, 2020 , ... ... Phase I of a Small Business Innovation Research (SBIR) program funded by the ... Century: Rapid Toxin Detection in the Field”. The project’s goal was to engineer ...
Breaking Biology Technology:
Cached News: